Fierce Biotech August 26, 2024
Alzheimer’s disease research and drug development is evolving at a rapid pace. Decades of research has led to the approval of the first disease-modifying drugs and new pathological discoveries. The first blood-based biomarker tests will bring equitable access to screening and diagnosis while accelerating clinical research. These major breakthroughs in the last few years alone represent a pivotal time in the Alzheimer’s disease landscape.
“This is an unprecedented time for Alzheimer’s research. Significant advances have been made in understanding pathological factors affecting disease, long-awaited disease-modifying treatments have been approved and more convenient diagnostic tools are becoming available – all major steps in changing the course and impact of this once-elusive disease,” stated Dr. David Morgan, Director of the Alzheimer’s Alliance...
Today's Sponsors
Today's Sponsor